August Troendle Sells 3,728 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 3,728 shares of the company’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $600.85, for a total transaction of $2,239,968.80. Following the completion of the sale, the chief executive officer directly owned 642,456 shares of the company’s stock, valued at $386,019,687.60. The trade was a 0.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Medpace Price Performance

Shares of MEDP stock traded up $14.52 during midday trading on Wednesday, hitting $585.49. The company had a trading volume of 580,873 shares, compared to its average volume of 364,017. The company’s 50 day simple moving average is $498.48 and its 200 day simple moving average is $493.41. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The stock has a market cap of $16.34 billion, a price-to-earnings ratio of 34.32, a PEG ratio of 2.63 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. During the same period last year, the firm posted $3.10 EPS. Medpace’s quarterly revenue was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts anticipate that Medpace Holdings, Inc. will post 17.55 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on MEDP shares. Robert W. Baird upped their target price on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Royal Bank Of Canada upped their price target on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 price target on Medpace in a report on Thursday, July 23rd. Finally, Mizuho raised their price objective on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Two analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $584.18.

Institutional Trading of Medpace

A number of hedge funds have recently made changes to their positions in the company. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Steigerwald Gordon & Koch Inc. purchased a new stake in Medpace during the 4th quarter worth $30,000. Elyxium Wealth LLC purchased a new stake in Medpace during the 4th quarter worth $30,000. Allied Private Wealth LLC acquired a new position in Medpace in the 2nd quarter worth $31,000. Finally, Basecamp Wealth Advisors LLC lifted its holdings in Medpace by 187.5% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 69 shares of the company’s stock worth $33,000 after buying an additional 45 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.